Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.33 |
| ▸ | FEN1 | P39748 | 8/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SCN1A | P35498 | 2/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963490 | 0.82 | NSD2 (0.43) | NSD2PIP4K2CSGK1ALOX5APFEN1 | |
| SCHEMBL2968069 | 0.79 | TP53BP1 (0.40) | KCNA5ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL13203024 | 0.76 | KAT2B (0.40) | KCNA5PIP4K2C | |
| SCHEMBL2971174 | 0.76 | KDM4E (0.38) | PIP4K2CCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2963433 | 0.76 | KMT2A (0.43) | CYP1A2CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL2968634 | 0.74 | NSD2 (0.42) | NSD2ALOX5APFEN1KDM4EALDH1A1 | |
| SCHEMBL13203031 | 0.74 | PRKCI (0.41) | KCNA5 | |
| SCHEMBL6108893 | 0.68 | EPAS1 (0.50) | KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL13203016 | 0.65 | HSP90AA1 (0.46) | — | |
| SCHEMBL2977913 | 0.65 | KMT2A (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | claimed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | NSD2 1687/4885KCNA5 4454/4885PIP4K2C 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.